Aims/hypothesis Pathophysiological similarities between latent autoimmune diabetes in adults (LADA) and type 1 diabetes indicate an overlap in genetic susceptibility. HLA-DRB1 and HLA-DQB1 are major susceptibility genes for type 1 diabetes but studies of these genes in LADA have been limited. Our aim was to define patterns of HLAencoded susceptibility/protection in a large, well characterised LADA cohort, and to establish association with disease and age at diagnosis. Materials and methods Patients with LADA (n= 387, including 211 patients from the UK Prospective Diabetes Study) and non-diabetic control subjects (n=327) were of British/Irish European origin. The HLA-DRB1 and -DQB1 genes were genotyped by sequence-specific PCR. Results As in type 1 diabetes mellitus, DRB1*0301_DQB1 , respectively). These genotypes and those containing DRB1*0401 and DQB1*0302 associated with a younger age at diagnosis in LADA, whereas genotypes containing DRB1*1501 and DQB1*0602 associated with an older age at diagnosis.
Introduction
Latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus result from islet beta cell autoimmune destruction and are characterised by the presence of circulating islet autoantibodies. However, the later age of onset and the relatively less acute clinical onset of LADA can result in a clinical diagnosis of type 2 diabetes [1] . Differences in genetic susceptibility could contribute to the variation in both age and clinical severity at onset of autoimmune diabetes.
The HLA gene region is the major susceptibility locus in type 1 diabetes, accounting for 42% of the total familial risk; primary susceptibility is conferred by the HLA-DRB1 and HLA-DQB1 genes, and the highest risk is from DRB1*04-DQB1*0302 and DRB1*0301-DQB1*0201 haplotypes, present in ∼90% of type 1 diabetic patients [2] . In type 1 diabetes, the DRB1*0301 and DRB1*0401 alleles exhibit positive synergism such that the DRB1*0401/ DRB1*0301 genotype confers greater risk than either of the two alleles alone [3] . In addition, DRB1*0301/ DRB1*0401 and DQB1*0201/DQB1*0302 genotypes occur more frequently in type 1 diabetic patients diagnosed at earlier ages [4] . Heterogeneity in disease risk conferred by the DRB1*04-DQB1*0302 haplotype depends upon the allelic subtype of the DR4 antigen specificity present on it: DRB1*0401, *0402 and *0405 associate with increased susceptibility, whereas *0403, *0406 and *0407 confer protection [5] . The DRB1*1501-DQB1*0602 haplotype, which is negatively correlated with age at diagnosis, is considered to be protective against type 1 diabetes [6] .
Although the HLA-DRB1 and HLA-DQB1 genes are good candidate loci for LADA, HLA association studies in LADA have been hampered by small sample sizes and low genotyping resolution. Predisposing effects of DRB1*0301 and DRB1*0401 have been demonstrated, but results have been inconsistent [7] [8] [9] and a protective effect of DQB1*0602 has not been confirmed throughout [8, 10] . The largest study, using UK Prospective Diabetes Study subjects (UKPDS), employed low-resolution typing restricted to detection of HLA-DRB1 susceptibility variants DRB1*03 and DRB1*04 [7] . This demonstrated an increased frequency of the DRB1*03/DRB1*04 heterozygote in LADA [7] . However, protective variants were not examined and HLA-DQB1 allele analysis was restricted to determination of aspartate-57, a putative susceptibility determinant for type 1 diabetes [7] .
This investigation extends the previous study [7] by using higher resolution typing and a larger LADA cohort. The aims were to (1) establish association patterns of HLA with disease and compare these with previously reported observations made in type 1 diabetes and (2) determine the relationship of HLA-DRB1 and HLA-DQB1 genotypes with age at diagnosis.
Subjects and methods
Subjects LADA subjects (n=378) were from the UKPDS (n=211), the Warren 2 Repository (W2, n=130) [11] and the Exeter Young-Onset Type 2 Diabetes Study (YT2D, n= 37) [12] . They were initially diagnosed with type 2 diabetes and were antibody-positive (for GAD and/or islet antigen 2A, IA-2A), with no requirement for insulin within 3 months after diagnosis. The control population comprised normoglycaemic, GADA/IA-2A-negative spouses/friends of probands recruited as part of the Diabetes in Families study (DIF, n=327). All subjects were unrelated and of British/Irish European origin (Table 1) . Informed consent was obtained from all subjects, and all studies were carried out in accordance with the principles of the Declaration of Helsinki (1975 Helsinki ( , 1983 Helsinki ( , 2000 .
Genotyping
The HLA-DRB1 and HLA-DQB1 genes were genotyped using sequence-specific PCR (PCR-SSP) [13] . Samples with inferred haplotypes that were uncommon or did not conform to known linkage disequilibrium patterns in UK Europids were regenotyped (n=27). Duplicate sample (n=15) genotyping concordance was 100% for both loci and success was >95%.
Statistical methods Homogeneity (between LADA groups) and case-control association testing was performed using standard contingency table methods in StatXact 6 (Cytel Software, Cambridge, MA, USA). As appropriate, exact p values were calculated. Haplotype frequencies were esti-mated using the expectation maximization algorithm implemented in HelixTree (Golden Helix, Bozeman, MT, USA). For diplotype analyses, the most probable haplotype pair was assigned to each individual and >97.8% of assigned haplotypes had posterior probabilities >0.999. Distributions of allele, genotype, haplotype and diplotype frequencies between cases and controls were assessed by 2×n contingency tables (pooling categories with frequencies <1%). Where global tests of association indicated significant differences, variants with frequency >5% were tested for disease association by 2×2 contingency table analysis. Association of age at diagnosis with genotype was initially explored using recursive partitioning, as implemented in HelixTree. Linear regression modelling (SPSS, version 13.0; SPSS, Chicago, IL, USA) was subsequently performed for genotypes containing alleles associated with type 1 diabetes and/or shown to be associated with age at diagnosis. Power calculations (Quanto, version 1.0; http://hydra.usc.edu/ gxe, last accessed in September 2006) indicated that our sample size provided >80% power to detect an odds ratio (OR) >1.85 for a minor allele frequency of 5% under the additive model. No corrections for multiple testing were applied and a p value of <0.05 was deemed significant.
Results
Allele frequency distributions between the UKPDS, W2 and YT2D LADA groups did not significantly differ at HLA-DRB1 and HLA-DQB1 (p=0.20 and 0.81, respectively). Accordingly, genotyping data of the three patient groups were combined, forming a single group ('LADA'), and compared with control subjects.
The overall distribution of allele frequencies at HLA-DRB1 and HLA-DQB1 differed significantly between LADA and control subjects (both p<0.0001). Analysis of individual alleles showed predisposing effects of DRB1*0301 (OR=3.08, 95% CI 2.32-4.11), DRB1*0401 (OR=1.79, 95% CI 1.35-2.38), DQB1*0201 (OR=3.19, 95% CI 2.40-4.26) and DQB1*0302 (OR=2.38, 95% CI 1.77-3.25) ( Table 2 ). Protection was conferred by DRB1*0403(06/07) (OR=0.37, 95% CI 0.13-0.97), DRB1*1101(04) (OR = 0.25, 95% CI 0.12-0.48), DRB1*1501-06 (OR = 0.20, 95% CI 0.13-0.32), DQB1*0301 (OR=0.51, 95% CI 0.37-0.69), DQB1*0303 (OR=0.29, 95% CI 0.14-0.57) and DQB1*0602 (OR=0.21, 95% CI 0.13-0.34) ( Table 2) .
The distribution of HLA-DRB1 and HLA-DQB1 genotypes differed significantly between LADA and control subjects (p<0.0001; see Electronic supplementary material [ESM] Tables 1 and 2 , respectively). Specifically, increased susceptibility to LADA was conferred by genotypes, DRB1*0301/DRB1*0401 (OR = 5.14, 95% CI 2.68-10.69), DRB1*0301/DRB1*0301 (OR = 4.51, 95% CI 1.93-12.23), DRB1*0301/DRB1*0701 (OR=2.38, 95% CI 1.13-5.38), DQB1*0201/DQB1*0302 (OR=6.88, 95% CI 3.54-14.68), DQB1*0201/DQB1*0201 (OR = 5.11, 95% CI 2.21-13.77), DQB1*0201/DQB1*0202 (OR= 2.47, 95% CI 1.04-6.51), DQB1*0201/DQB1*0501 (OR= (Table 3) . Additionally, protective effects of DRB1*0701/DRB1*1501-06 (OR=0.05, 95% CI 0.001-0.31) and DQB1*0301/DQB1*0602 (OR=0.11, 95% CI 0.02-0.38) were observed ( Table 3) . The highest point estimate for genotypic risk at HLA-DRB1 was seen in the DRB1*0301/DRB1*0401 heterozygotes, though this was not significantly greater than the estimate for either homozygote group (data not shown).
DRB1_DQB1 haplotype distribution was different between LADA and control subjects (p<0.0001; ESM Table 3 ). H a p l o t y p e s D R B 1 * 0 3 0 1 _ D Q B 1 * 0 2 0 1 a n d DRB1*0401_DQB1*0302 were predisposing (OR=3.08, 95% CI 2.32-4.12; and OR=2.57, 95% CI 1.80-3.73, respectively) whereas DRB1*1101(04)_DQB1*0301 and DRB1*1501-06_DQB1*0602 (OR=0.25, 95% CI 0.12-0.48; and OR=0.21, 95% CI 0.13-0.34, respectively) conferred protection against LADA (Table 4) .
Similarly, DRB1_DQB1 diplotype frequencies differed significantly between LADA and control subjects (p< 0.0001; ESM Table 4) , with DRB1*0301_DQB1*0201-DRB1*0401_DQB1*0302 and DRB1*0301_DQB1*0201-DRB1*0301_DQB1*0201 occurring more frequently in LADA compared with control subjects (OR=8.70, 95% CI 3.67-25. 13 predisposing effect of DRB1*0301_DQB1*0201-DRB1*0701_DQB1*0202 was also observed (OR=2.46, 95% CI 1.04-6.49, p=0.048). Diagnostic criteria for LADA have been proposed, including age at diagnosis >30 years and no clinical requirement for insulin within 6 months after diagnosis [14] . Using these criteria, we repeated the analyses, excluding 50 non-compliant cases. The effect sizes (odd ratios) were comparable (data not shown) with those described above.
Within the LADA group, the DRB1*0301/*0401 genotype associated with a younger age of diagnosis (mean age± SD in carriers vs non-carriers, 42.1 ±10.3 vs 46.6 ± 10.2 years, p = 0.0016), as did possession of the DRB1*0401 allele (43.8±9.8 vs 47.4±10.5 years, p= 0.00075). Similarly, an earlier age of diagnosis was associated with the DQB1*0201/DQB1*0302 genotype (42.8 ± 9.8 vs 46.5 ± 10.3 years, p = 0.0051) and with possession of the DQB1*0302 allele (44.3±9.8 vs 46.9± 10.5 years, p = 0.018). Conversely, patients carrying DRB1*1501-06 were older at diagnosis than those not carrying this allele (50.3±10.7 vs 45.6±10.2 years, p= 0.030), as were carriers of DQB1*0602 (50.3±10.7 vs 45.5±10.2 years, p=0.029).
Discussion
The major LADA susceptibility determinants at the two loci were DRB1*0301, DRB1*0401, DQB1*0201 and DQB1*0302. This confirms previously reported genotype associations of DRB1*0301/DRB1*0401, DRB1*0301/ DRB1*0301, DQB1*0201/DQB1*0201, DQB1*0201/ DQB1*0302 and DQB1*0302/DQB1*0302 in LADA [7, 8] . This is the first report to demonstrate that DR4 antigen specificity subtypes confer differential risk of LADA: DRB1*0401 conferred susceptibility to LADA, whereas DRB1*0403(06/07) had a protective effect. The synergistic effects of the DRB1*0301 and DRB1*0401 alleles reported in type 1 diabetes [3] were not statistically significant in LADA, although the greatest point estimate for genotypic risk at HLA-DRB1 was observed for DRB1*0301/ DRB1*0401 heterozygotes, which conferred an approximately 5-fold risk of disease (OR=5.14, 95% CI 2.68-10.69, p=1.3×10 −8 ).
The major protective alleles in our LADA cohort were DRB1*1501-06 and DQB1*0602, as seen in Swedish patients [10] though not in Finns [8] . DRB1*1101(04), DQB1*0301 and DQB1*0303 were also protective, as seen in type 1 diabetes [2] . However, we found that DRB1_DQB1 haplotypes/diplotypes were very strongly associated with LADA and, in some cases, could account for the genotype/allele effects, e.g. protection conferred by DRB1*1101(04)_DQB1*0301. The age-related associations observed in this study are similar to those reported in type 1 diabetes and LADA [4, 6, 7] . We conclude that the architecture of HLA-conferred susceptibility to LADA is similar to that observed in type 1 diabetes, although individual effect sizes may differ. Susceptibility conferred by the insulin gene region is indistinguishable from that observed in type 1 diabetes [15] . Thus, similarities in genetic predisposition conferred by the two major type 1 diabetes susceptibility loci suggest that adult-onset autoimmune diabetes is an age-related extension of the pathophysiological process presenting as type 1 diabetes in children.
